H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo

2019/02/15 by André Bortolini Silveira, André B. Silveira, Lawryn H. Kasper +27 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Glioma Diagnosis and Treatment #Cancer-related molecular mechanisms research #Chromatin Remodeling and Cancer

paper · doi:10.1007/s00401-019-01975-4

Cited by

• Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer. [europepmc]
• CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism. [europepmc]
• Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. [europepmc]
• Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. [europepmc]
• Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. [europepmc]
• Epigenomic Reprogramming as a Driver of Malignant Glioma. [europepmc]
• H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation. [europepmc]
• Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer. [europepmc]
• Solid tumours hijack the histone variant network. [europepmc]
• A novel proteomics approach to epigenetic profiling of circulating nucleosomes. [europepmc]
• The dark side of histones: genomic organization and role of oncohistones in cancer. [europepmc]
• Oncohistones: a roadmap to stalled development. [europepmc]
• Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours. [europepmc]
• Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. [europepmc]
• EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. [europepmc]
• New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma. [europepmc]
• Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. [europepmc]
• The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential. [europepmc]
• Oncohistones: Exposing the nuances and vulnerabilities of epigenetic regulation. [europepmc]
• A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. [europepmc]
• BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. [europepmc]
• Oncohistones: Hijacking the histone code. [europepmc]
• Signaling pathways in brain tumors and therapeutic interventions. [europepmc]
• Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. [europepmc]
• Histone mutations in cancer. [europepmc]